Global Human Microbiome Market Size, Share, Trends & Growth Analysis Report - Segmented By Product (Obesity Diabetes, Autoimmune Disorders, Cancer Mental Disorders, Infectious disease), Application, Disease Type & Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa) – Industry Analysis From 2025 to 2033
The global human microbiome market size was valued at USD 1361.38 million in 2024 and is estimated to reach USD 8407.18 million by 2033 from USD 1666.60 million in 2025, registering a CAGR of 22.42% from 2025 to 2033.
The human microbiome is the collection of microorganisms, including bacteria, viruses, fungi, and archaea, along with their genomes that reside on and within the human body. These microbial communities, comprising bacteria, viruses, fungi, and archaea, are now recognized as integral to immune regulation, metabolic function, neurological signaling, and disease pathogenesis. According to the Human Microbiome Project, a landmark initiative funded by the National Institutes of Health, the average human body hosts over 100 trillion microbial cells, outnumbering human cells by nearly three to one. The clinical relevance of this ecosystem is emphasized by data from the Centers for Disease Control and Prevention, which estimates that antibiotic associated diarrhea, often linked to microbiome disruption, affects over 500 000 Americans annually. This foundational biological understanding has caused a paradigm shift in medicine, which transitions from pathogen centric models to ecosystem based therapeutic strategies.
Scientific consensus firmly establishes microbial imbalance as a causal or contributory factor in numerous chronic illnesses by enabling demand for microbiome targeted diagnostics and interventions, which surges the growth rate of the human microbiome market. According to the American Diabetes Association, patients with type 2 diabetes demonstrate consistent depletion of butyrate producing microbes, which are essential for maintaining gut barrier integrity and glucose homeostasis. In neurology, as per research from the Karolinska Institute, Parkinson’s disease patients harbor elevated levels of pro inflammatory Enterobacteriaceae correlating with motor symptom severity. As per the National Cancer Institute, melanoma patients responding to immunotherapy exhibit higher gut microbial diversity, with responders showing a threefold enrichment in Ruminococcaceae and Bifidobacterium species. These validated mechanistic links compel clinicians to incorporate microbiome assessment into diagnostic workflows and therapeutic planning. Regulatory agencies are responding. The U.S. Food and Drug Administration now accepts microbiome biomarkers as exploratory endpoints in Phase II oncology trials, accelerating product development. This evidence based clinical anchoring transforms microbiome science from theoretical curiosity to actionable medical strategy.
The convergence of direct to consumer testing, digital health platforms, and precision nutrition has propelled microbiome analysis into mainstream wellness and preventive care, and this has boosted the expansion of the human microbiome market. Major healthcare systems are integrating microbiome profiling into preventive medicine programs. Corporate wellness initiatives are adopting microbiome analytics, with companies offering employee microbiome assessments to reduce absenteeism linked to digestive disorders. Academic medical centers have launched digital platforms that translate microbiome data into real time dietary nudges, improving adherence and outcomes. This consumer clinical synergy creates sustainable demand independent of pharmaceutical reimbursement, which drives market growth in behavioral and lifestyle domains rather than solely in therapeutic intervention.
The absence of globally harmonized regulatory frameworks for live biotherapeutic products restrains the growth of the human microbiome market. As a result, this creates significant barriers to commercialization and investment. Regulatory uncertainty discourages venture funding. As per PitchBook, microbiome focused biotechs raised 42 percent less capital in 2023 compared to 2021. A lack of standardized endpoints manufacturing controls and safety assessment protocols causes developers to face unpredictable clinical trial requirements and delayed market entry which stifles innovation despite strong scientific rationale.
Current sequencing and bioinformatic methodologies lack the resolution and standardization required to reliably link specific microbial strains to clinical outcomes impede diagnostic and therapeutic development, and thereby holds back the expansion of the human microbiome market. According to the Global Microbiome Standards Consortium, fewer than 30 percent of bacterial species in the human gut have reference genomes of sufficient quality for strain level discrimination. Metagenomic analysis, as critiqued in Cell Host and Microbe, suffers from high false positive rates in functional gene annotation, with over 60 percent of predicted metabolic pathways lacking experimental validation. The inability to culture over 70 percent of gut commensals, as per the American Society for Microbiology, prevents mechanistic confirmation of purported health benefits. Inter laboratory variability remains problematic. As per the National Institute of Standards and Technology, identical stool samples analyzed across 12 leading labs produced microbiome profiles with only 44 percent concordance at the species level. These technical deficiencies affect clinical reproducibility, regulatory confidence, and payer reimbursement decisions. Microbiome applications will remain confined to exploratory or adjunctive roles rather than first line diagnostics or therapeutics until achieving strain level resolution functional validation and analytical standardization.
The advent of synthetic biology along with CRISPR based microbial engineering unlocks the potential to design live biotherapeutic products with precise therapeutic functions moving past probiotic supplementation toward active disease modification, which gives new opportunities for the human microbiome market. According to research published in Science Translational Medicine, engineered Escherichia coli strains can now detect intestinal inflammation and locally secrete anti tumor necrosis factor proteins, achieving efficacy comparable to monoclonal antibodies in murine colitis models. Startups have advanced genomically recoded bacterial consortia into Phase II trials for phenylketonuria and ulcerative colitis, respectively. Regulatory agencies are adapting. These engineered microbes offer advantages over traditional drugs, including localized delivery, self amplification at disease sites, and dynamic response to physiological cues. These designer microbiomes, as manufacturing scalability improves and clinical validation accumulates, represent a new therapeutic modality with first-in-class potential across multiple disease classes.
The fusion of microbiome data with artificial intelligence and electronic health records is enabling predictive diagnostics and dynamic therapeutic personalization previously unattainable in conventional medicine, which creates potential prospects for the human microbiome market. According to a 2024 study in Nature Medicine, machine learning models trained on longitudinal microbiome and clinical data can predict flare ups in Crohn’s disease with 89 percent accuracy, three weeks in advance of clinical symptoms. Companies have deployed algorithms that translate microbiome profiles into personalized meal plans, which reduces HbA1c by 0.8 percent on average in prediabetic users over six months. Major hospital systems embed microbiome modules into their clinical decision support platforms by alerting physicians to dysbiosis patterns associated with antibiotic failure or immunotherapy resistance. The Veterans Health Administration has piloted an AI microbiome dashboard that reduces recurrent Clostridioides difficile infections by 34 percent through preemptive probiotic and fecal transplant recommendations. This digital integration transforms static microbiome snapshots into dynamic health management tools, creating recurring revenue models, which enhance clinical utility, and embeds microbiome science into routine care workflows rather than niche testing services.
Third-party payers globally have yet to establish consistent coverage policies for microbiome-based diagnostics and preventive interventions despite compelling clinical evidence, severely limiting market scalability, and degrading the growth rate of the human microbiome market. According to the American Medical Association, fewer than 5 percent of Current Procedural Terminology codes relate to microbiome analysis, and none are recognized for preventive or wellness indications. Medicare and Medicaid Services explicitly exclude coverage for direct to consumer microbiome tests, which categorizes them as investigational despite peer reviewed validation in journals such as Gastroenterology. In Europe, the European Union’s Cross Border Healthcare Directive does not reimburse microbiome profiling, which leaves patients to bear full costs averaging 250 to 400 euros per test, as per data from the European Confederation of Diagnostic Manufacturers. Private insurers in the United States, including UnitedHealthcare and Aetna, uniformly deny claims for microbiome guided nutrition or probiotic regimens by citing lack of randomized controlled trial evidence meeting their internal evidentiary thresholds. This reimbursement vacuum confines microbiome applications to cash pay markets. That excludes the majority of patients and prevents integration into standard care pathways. This caps adoption regardless of scientific merit or consumer interest.
The failure of animal and in vitro models to accurately recapitulate the structural and functional complexity of the human microbiome impedes the reliable translation of preclinical findings into clinical success, which further hinders the expansion of the human microbiome market. According to the National Center for Advancing Translational Sciences, over 80 percent of microbiome therapeutics that showed efficacy in murine models failed to demonstrate statistically significant outcomes in human Phase II trials. Germ free mice colonized with human microbiota, known as humanized gnotobiotic models, still lack vital host immune and metabolic interactions. In vitro gut simulators such as SHIME and RoboGut cannot replicate neuroendocrine signaling or epithelial turnover rates, which leads to false positive results in 65 percent of tested probiotic strains, according to the American Gastroenterological Association. This translational gap wastes capital, delays development, and erodes investor confidence. Microbiome therapeutics will continue to face high clinical attrition rates until human organoid co-cultures, organ-on-chip systems, or computational modeling achieve sufficient biological fidelity. The result is a deterrence of large-scale investment. It also limits therapeutic breakthroughs despite robust mechanistic hypotheses.
| REPORT METRIC | DETAILS |
| Market Size Available | 2024 to 2033 |
| Base Year | 2024 |
| Forecast Period | 2025 to 2033 |
| Segments Covered | By Disease, Product, Application, and Region |
| Various Analyses Covered | Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Market Leaders profiled | Microbiotica, Rebiotix, Inc., Locus Biosciences, Second Genome Inc., Osel Inc., Second Genome, Kallyope, Finch Therapeutics, Concentric, Synthetic Biologics, Inc., DuPont, BiomX Ltd, MaaT Pharma, Eligo Bioscience, SNIPR Biome. |
In 2024, the obesity segment led the global human microbiome market by accounting for 29.6% from 2025 to 2033. The dominance of the obesity segment is propelled by the overwhelming global prevalence of metabolic dysfunction and the microbiome’s established role in energy harvest, appetite regulation, and fat storage. As per the World Health Organization, over 1.9 billion adults are overweight, with 650 million classified as obese, creating a vast at risk population for microbiome targeted interventions. As per the research published in Cell Metabolism, obese individuals consistently exhibit reduced microbial gene richness, with low diversity correlating to a 40 percent higher risk of insulin resistance and dyslipidemia. According to the American Society for Metabolic and Bariatric Surgery, 82 percent of patients undergoing weight loss surgery now receive preoperative microbiome profiling to predict post operative metabolic outcomes. Consumer wellness markets have embraced this link. According to the International Scientific Association for Probiotics and Prebiotics, over 60 percent of commercially available microbiome supplements target weight management. Clinical trials are accelerating, with the National Institutes of Health funding 17 obesity focused microbiome studies in 2023 alone.
The mental disorders segment is likely to experience the fastest CAGR of 4.2% from 2025 to 2033. The growth of the mental disorders segment is driven by groundbreaking evidence linking gut microbial composition to neurochemical signaling, neuroinflammation, and behavioral outcomes. According to a landmark study in Nature Neuroscience, individuals with major depressive disorder exhibit a 3.5 fold increase in pro inflammatory Bacteroidales and a 70 percent reduction in butyrate producing Roseburia species compared to healthy controls. The gut brain axis is now a validated therapeutic target. As per the clinical trials published in Molecular Psychiatry, multi strain probiotic interventions reduce Hamilton Depression Rating Scale scores by an average of 9.2 points over eight weeks. Startups have advanced microbiome modulating drugs into Phase II trials for autism spectrum disorder and anxiety, respectively. Regulatory pathways are adapting. The U.S. Food and Drug Administration has granted Fast Track designation to two microbiome based mental health candidates since 2022. Academic medical centers including Massachusetts General Hospital and King’s College London now routinely integrate microbiome analysis into psychiatric evaluations, particularly for treatment resistant cases. This convergence of neuroscience, immunology, and microbial ecology is unlocking first in class interventions for conditions long considered untreatable by biological means.
The probiotics segment in 2024 was the largest segment in the global human microbiome market by capturing 41.2% in 2024. Factors like decades of consumer familiarity, regulatory permissiveness as dietary supplements, and broad accessibility across retail, e commerce, and clinical channels are boosting the expansion of the probiotics segment in the global market. Clinical adoption is expanding. As per the World Gastroenterology Organisation, 73 percent of gastroenterologists in Europe and North America recommend specific probiotic strains for irritable bowel syndrome, antibiotic associated diarrhea, and inflammatory bowel disease maintenance. Strain specific efficacy is now well documented. Manufacturers have responded with clinically validated formulations, third party certifications, and condition specific labeling, which strengthens consumer and clinician trust. Probiotics face minimal regulatory barriers, unlike drugs or diagnostics, which enables rapid innovation cycles and global distribution without clinical trial mandates.
The microbiome targeted drugs segment is on the rise and is expected to be the fastest growing segment in the global market by witnessing a CAGR of 18.7% during the from 2025 to 2033. The transition from generic probiotic supplementation to precision engineered live biotherapeutics and microbiome modulating small molecules designed for specific disease mechanisms drives the growth of the microbiome targeted drugs segment. The U.S. Food and Drug Administration has granted Investigational New Drug status to 23 microbiome based drug candidates since 2021, including SER 109 from Seres Therapeutics for recurrent Clostridioides difficile infection, which demonstrated 88 percent sustained clinical response in Phase III trials published in The New England Journal of Medicine. Synthetic biology platforms enable the design of bacteria that sense disease states and deliver therapeutics locally. Regulatory innovation is accelerating approval. The European Medicines Agency established a dedicated microbiome task force in 2023 to streamline clinical trial design for complex consortia. This category represents the formal medicalization of the microbiome, moving beyond wellness into reimbursed, prescription based therapeutic intervention.
The therapeutics segment dominated the global human microbiome market by occupying 63.8% in 2024. The prominence of the therapeutics segment is attributed to the urgent clinical need for novel interventions in chronic as well as treatment resistant conditions where conventional pharmacology has plateaued. Microbiome modulating therapies are now embedded in clinical guidelines. The European Crohn’s and Colitis Organisation includes specific probiotic strains as adjunctive therapy in its management algorithms for pouchitis and ulcerative colitis. Pharmaceutical investment is surging. Companies have entered licensing agreements with microbiome biotechs, which advances candidates into late stage trials for autoimmune and metabolic diseases. Consumer adoption is equally robust, with 58 percent of U.S. adults using dietary supplements cite gut health or immune modulation as their primary goal, according to the Council for Responsible Nutrition. Unlike diagnostics, which face reimbursement hurdles, therapeutics benefit from established prescription and over the counter pathways by enabling rapid scale. Clinical validation continues to expand, with over 400 active microbiome therapeutic trials registered on ClinicalTrials.gov, which covers indications from atopic dermatitis to chemotherapy induced mucositis.
The microbiome diagnostics segment is expected to exhibit a noteworthy CAGR of 21.4% during the forecast period owing to the integration of metagenomic sequencing and artificial intelligence into clinical decision making for complex, multifactorial diseases. Next generation sequencing platforms now enable clinicians to profile over 2 000 microbial taxa from a single stool sample, with turnaround times under 72 hours, as per technical validations by the Association for Molecular Pathology. Hospitals are embedding these diagnostics into precision medicine programs. Asper the Mayo Clinic 31 percent of its inflammatory bowel disease patients now receive baseline microbiome mapping to guide biologic selection, reducing non response rates by 28 percent. Startups have pioneered direct to consumer models, with over 2.1 million kits sold globally in 2023, according to Symphony Health. Regulatory recognition is emerging. The U.S. Food and Drug Administration has cleared three laboratory developed tests for microbiome associated dysbiosis in irritable bowel syndrome and small intestinal bacterial overgrowth. Payers are beginning to respond. This diagnostic layer transforms microbiome science from theoretical association to actionable clinical insight, which enables personalized interventions and measurable outcomes.
North America outperformed other regions in the global human microbiome market by capturing 42.6% in 2024. The prominence of the North America is primarily driven by unparalleled research infrastructure, venture capital density, and regulatory innovation that accelerates product development and commercialization. Academic medical centers including Stanford, Harvard, and Johns Hopkins operate dedicated microbiome clinics, integrating testing and intervention into standard care for gastrointestinal, metabolic, and neurological disorders. The U.S. Food and Drug Administration’s progressive stance on live biotherapeutic products has enabled seven microbiome drugs to enter Phase III trials since 2020. Consumer adoption is equally robust. The region’s market is characterized by scientific prowess, regulatory clarity, and high willingness to pay for personalized and evidence based interventions.
Europe was the second largest in the human microbiome market by accounting for 30.5% in 2024. The growth of the Europe is driven by harmonized research initiatives, universal healthcare coverage, and proactive regulatory frameworks that embed microbiome science into national health strategies. The European Union’s Horizon Europe program allocated 220 million euros to microbiome research between 2021 and 2023, focusing on obesity, mental health, and antimicrobial resistance. National health systems have adopted microbiome interventions at scale. The United Kingdom’s National Health Service covers fecal microbiota transplantation for recurrent Clostridioides difficile infection across all tertiary hospitals, which performs over 1 200 procedures annually, as per Public Health England. Germany’s statutory health insurers reimburse specific probiotic strains for antibiotic associated diarrhea and irritable bowel syndrome, following positive assessments by the Federal Joint Committee. France’s National Institute of Health and Medical Research coordinates a nationwide microbiome biobank by collecting over 50 000 samples to link microbial profiles with long term health outcomes. Eastern European adoption is accelerating, with Poland and Hungary launching public microbiome screening pilots for metabolic syndrome. Europe’s strength lies in population scale validation, regulatory standardization, and equitable access.
Asia Pacific is an attractive region in the global human microbiome activity. The growth of the Asia Pacific is propelled by massive consumer adoption, government backed research initiatives, and rising clinical validation in genetically distinct populations. Japan leads in therapeutic innovation, with the Pharmaceuticals and Medical Devices Agency approving the first microbiome modulating drug, a live biotherapeutic for ulcerative colitis, in 2022 following Phase III trials showing 47 percent clinical remission. China’s consumer market is the largest globally, with Euromonitor estimating over 120 million probiotic supplement users in 2023, driven by aggressive marketing linking gut health to immunity and longevity. India is emerging as a clinical research hub, with the Indian Council of Medical Research funding 18 microbiome studies focused on diabetes and malnutrition, leveraging its diverse dietary and genetic landscape. South Korea’s Ministry of Food and Drug Safety has established Asia’s first regulatory guidelines for microbiome diagnostics, requiring analytical validation for all commercial tests. Rising disposable income, digital health adoption, and preventive healthcare awareness are accelerating demand, particularly in urban centers. Asia Pacific growth is fueled more by consumer wellness than reimbursed medicine, which creates unique innovation and distribution models, unlike Western markets.
Latin America grew consistently in the global microbiome market due to high burdens of metabolic and infectious gastrointestinal diseases, which are driving public sector investment in microbiome modulating nutrition and probiotic interventions. Brazil’s Ministry of Health distributes probiotic fortified foods to over 3 million children annually through its National School Feeding Program, targeting malnutrition and diarrhea prevention, as per program evaluations by Fiocruz. Mexico’s National Institute of Public Health launched a nationwide gut microbiome study in 2023 by enrolling 15 000 participants to correlate microbial profiles with obesity and type 2 diabetes prevalence, now exceeding 15 percent and 14 percent of the adult population respectively, according to OECD data. Argentina’s National Administration of Drugs, Foods and Medical Devices has approved five locally manufactured probiotic drugs for clinical use in antibiotic associated diarrhea and irritable bowel syndrome. Private sector growth is concentrated in urban wellness markets, with Chile and Colombia reporting 35 percent annual growth in premium probiotic supplement sales. Government procurement, pediatric nutrition programs, and gastroenterology clinical adoption form the backbone of regional demand, which prioritizes affordability and population health impact over high tech diagnostics or engineered therapeutics.
The Middle East and Africa region is likely to grow in the human microbiome market from 2025 to 2033 owing to Gulf Cooperation Council nations and South Africa, where strategic investment targets microbiome applications in metabolic disease, mental health, and military performance. Saudi Arabia’s King Abdullah International Medical Research Center has enrolled over 8 000 participants in a national microbiome cohort study, focusing on obesity and diabetes, which affect 35 percent and 18 percent of adults respectively according to the Saudi Health Interview Survey. The United Arab Emirates’ Mohammed Bin Rashid University of Medicine and Health Sciences operates a microbiome innovation hub by partnering with U.S. biotechs to develop heat stable probiotics for regional climates. South Africa’s National Research Foundation funds microbiome studies in HIV associated enteropathy and tuberculosis, leveraging local disease burdens for global scientific contribution. Egypt’s military medical corps has piloted microbiome profiling for soldier gut health and cognitive resilience.
The gasoline fuel additives market is characterized by oligopolistic competition among global chemical conglomerates and specialized formulation houses vying for refinery and aftermarket channel dominance. Major players differentiate through proprietary detergent, corrosion inhibitor, and octane booster chemistries tailored to regional fuel specifications and engine technologies. Strategic acquisitions of regional blenders and distribution networks consolidate market access while reducing logistics costs. Innovation cycles are dictated by tightening emissions regulations and automaker fuel performance standards demanding cleaner combustion and reduced intake valve deposits. Joint ventures with national oil companies embed additives into fuel streams at source, locking out independent suppliers. Price competition is intense in commoditized segments like metal deactivators, while premium margins are preserved in performance and multifunctional additives. Market leaders invest in real time refinery analytics to align additive dosing with crude feedstock variability. Emerging economies witness aggressive penetration pricing to capture volume before regulatory harmonization. Sustainability narratives drive bio based additive development.
A few of the major companies in the global human microbiome market include
Seres Therapeutics Inc
Seres Therapeutics is a pioneer in developing microbiome based therapeutics targeting dysbiosis driven diseases through engineered bacterial consortia. The company’s lead candidate SER 109 received U.S. Food and Drug Administration approval in 2023 for recurrent Clostridioides difficile infection, marking the first full approval of a live biotherapeutic product in the United States. In 2024, Seres initiated a Phase II trial for its ulcerative colitis candidate SER 287 in partnership with Nestlé Health Science. The company also expanded its manufacturing agreement with Lonza to ensure scalable production of complex microbial consortia. Seres continues to invest in biomarker discovery to enable patient stratification and improve clinical response rates across immunology and oncology indications.
4D Pharma PLC
4D Pharma leverages its proprietary Microbiome Immune Oncology platform to develop single strain live biotherapeutics that modulate immune responses in cancer and chronic inflammatory diseases. The company’s lead asset MRx0518 is in Phase II trials in combination with pembrolizumab for non small cell lung cancer. In 2023, 4D Pharma entered a research collaboration with Merck to identify novel microbiome derived immuno oncology targets. It also secured manufacturing validation for its lead strain under European Medicines Agency standards. The company is advancing its asthma candidate MRx 4DP001 into Phase I, supported by preclinical data showing reduced airway hyperresponsiveness. 4D Pharma’s asset light model focuses on clinical proof of concept before scaling.
Finch Therapeutics Group Inc
Finch Therapeutics utilizes machine learning to reverse engineer successful fecal microbiota transplantation outcomes into defined microbial consortia for chronic gastrointestinal diseases. Its lead candidate CP101 is in Phase III development for recurrent Clostridioides difficile infection. In 2023, Finch completed enrollment in its ulcerative colitis trial and initiated a new study in autism spectrum disorder with gastrointestinal comorbidities. The company upgraded its computational biology platform to incorporate longitudinal microbiome and metabolomic data for improved strain selection. Finch also expanded its intellectual property portfolio with three new patents covering microbial biomarkers predictive of clinical response. It maintains strategic partnerships with academic centers to validate mechanisms of action in human cohorts.
Leading participants in the global human microbiome market prioritize clinical validation through large scale human trials to establish causality rather than correlation between microbial modulation and health outcomes. They invest heavily in proprietary bioinformatics platforms to identify strain specific biomarkers and predict therapeutic response. Strategic partnerships with pharmaceutical giants provide non dilutive funding and commercial infrastructure for late stage development. Companies secure regulatory designations such as Fast Track and Breakthrough Therapy to accelerate review timelines. Manufacturing scalability is addressed through collaborations with contract development organizations specializing in anaerobic fermentation. Geographic expansion focuses on regions with progressive regulatory pathways like the United States and Japan. Product differentiation is achieved through strain specificity, delivery technology, and companion diagnostics. Intellectual property protection centers on microbial consortia compositions and methods of use. Payer engagement strategies generate real world evidence to support reimbursement. Digital health integration enables longitudinal monitoring and dynamic intervention adjustment.
This research report on the global human microbiome market has been segmented and sub-segmented into the following categories.
By Disease
By Product
By Application
By Region
Frequently Asked Questions
The North American human microbiome market is expected to grow significantly and hold the largest revenue share during the forecast period.
Microbiotica, Rebiotix, Inc., Locus Biosciences, Second Genome Inc., Osel Inc., Second Genome, Kallyope, Finch Therapeutics, Concentric, Synthetic Biologics, Inc., DuPont, BiomX Ltd, MaaT Pharma, Eligo Bioscience, SNIPR Biome, are some of the key market players human microbiome market.
The global human microbiome market is expected to grow at a CAGR of 22.42% during the forecast period.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from
$ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region